Skip to main content
Search
Main content
Alzheimer's & dementia : the journal of the Alzheimer's Association
Published

Associations of <sup>18</sup>F-RO-948 tau PET with fluid AD biomarkers, Centiloid, and cognition in early AD continuum

Authors

Mahnaz Shekari, Armand González Escalante, Marta Milà-Alomà, Carles Falcon, David López-Martos, Gonzalo Sánchez-Benavides, Anna Brugulat-Serrat, Aida Niñerola-Baizán, Nicholas J Ashton, Thomas K Karikari, Juan Lantero-Rodriguez, Laia Montoliu-Gaya, Anniina Snellman, Theresa A Day, Jeffrey L Dage, Paula Ortiz-Romero, Matteo Tonietto, Edilio Borroni, Gregory Klein, Gwendlyn Kollmorgen, Margherita Carboni, Clara Quijano-Rubio, Eugeen Vanmechelen, Carolina Minguillón, Karine Fauria, Andrés Perissinotti, José Luis Molinuevo, Henrik Zetterberg, Kaj Blennow, Oriol Grau-Rivera, Marc Suárez-Calvet, Juan Domingo Gispert, ALFA Study

Abstract

Alzheimers Dement. 2026 Apr;22(4):e71176. doi: 10.1002/alz.71176.

ABSTRACT

INTRODUCTION: We examined neurofibrillary tangle (NFT) pathology using 18F-RO-948 tau positron emission tomography (PET) in cognitively unimpaired individuals and its associations with amyloid plaques, fluid biomarkers, and cognition in early preclinical Alzheimer's disease (AD).

METHODS: We analyzed 97 participants from the ALFA+ cohort with tau and amyloid PET, magnetic resonance imaging, fluid biomarkers (cerebrospinal fluid [CSF]/plasma), and cognitive data. Braak staging was applied, and correlations with biomarkers and cognitive measures were assessed. Receiver operating characteristic analyses evaluated biomarker performance in predicting tau PET positivity RESULTS: CSF and plasma tau phosphorylated at threonine 217 (p-tau217) showed the strongest correlation with early Braak I/II tau PET signal (r = 0.58, and r = 0.37, respectively), while plasma p-tau181 and p-tau181/Aβ42 showed moderate associations (r ∼ 0.25). However, positive predictive values were low (PPV = 0.09-0.33).

DISCUSSION: 18F-RO-948 PET detected early tau pathology in individuals with low to moderate amyloid load. Fluid biomarkers, especially in plasma, had limited predictive power but high negative predictive value, supporting their use in ruling out early tau pathology in preclinical AD.

PMID:41994995 | DOI:10.1002/alz.71176

UK DRI Authors

Profile picture of Henrik Zetterberg

Prof Henrik Zetterberg

Group Leader

Pioneering the development of fluid biomarkers for dementia

Prof Henrik Zetterberg